Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

Market Cap	$80.12M	P/E Ratio	N/A
52W High	$0.98	52W Low	$0.26
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	17.1%	52W Position	15.2%
Overall Score	39	Value Score	--
Quality Score	39	Technical Score	--

EPS Current Est	$-0.27	EPS Next Est	$-0.41
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VXRT	$0.37	+1.37%	677.77K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VXRT	$0.37	+1.4%	677.77K
3
4
5
6

VXRT

VXRT

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Vaxart Inc. Data in Excel

Get Vaxart Inc. Data in Excel